BLAINTRAVENOUSINJECTABLE
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
BRIUMVI (ublituximab) by TG Therapeutics, Inc. is cd20-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRIUMVI (ublituximab) is a CD20-directed cytolytic monoclonal antibody approved in December 2022 for intravenous infusion. It works by binding to CD20 antigen on B cells, triggering immune-mediated cell destruction. The drug is currently in peak commercial lifecycle stage.
$0.002BPart D
PeakEarly-stage revenue with modest Part D uptake (70 claims in 2023) suggests growth opportunity ahead for commercial teams as market awareness expands.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Started Oct 2026
120 enrolled
Myasthenia Gravis
An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
Started Oct 2026
20 enrolled
Down Syndrome Regression Disorder (DSRD)Down Syndrome (Trisomy 21)Neuroinflammatory / Neuropsychiatric Disorder
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Started Jul 2026
60 enrolled
Schizophrenia
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Started Jul 2026
240 enrolled
Relapsing Multiple Sclerosis
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Started May 2026
30 enrolled
Multiple Sclerosis (MS) - Relapsing-remitting
Worked on BRIUMVI at TG Therapeutics, Inc.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.